TELA Bio (TELA)
NASDAQ:TELA
Want to see TELA full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.22Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed constructive early progress with multiple meaningful positives: fully staffed U.S. commercial team, a major product launch (OviTex LTR), strong international performance (+41% in Europe), 16% unit growth, growing clinical evidence, and a board refresh to support scaling. These highlights were balanced against near-term financial pressures — modest 3% revenue growth in Q1, gross margin compression, a slightly wider net loss driven by higher interest expense, PRS utilization volatility due to concentration risk, and execution/timing risks tied to rep maturation and contract timing. Management expects an inflection in productivity as new hires reach the 6-month mark and reiterated at least 8% full-year revenue growth, signaling confidence in a stronger back half. Overall, the narrative is of early validation and building momentum, but with clear execution risks to realize the projected ramp.Company Guidance
Revenue and Guidance
Total revenue of $19.1M in Q1 2026, a 3% increase vs $18.5M in Q1 2025. Company reiterated full-year guidance of at least 8% revenue growth over 2025 and provided Q2 2026 revenue guidance of approximately $20M.
International / Europe Breakout
International revenue of $3.7M, up 41% year-over-year, driven entirely by the hernia portfolio. Strong UK performance and NHS value-based procurement selection of OviTex for complex abdominal procedures, with the company citing transferable cost and clinical benefits across EU health systems.
OviTex Unit Growth and Portfolio Strength
OviTex revenue of $12.6M (up from $12.1M) with unit volume growth of 16% YoY (5,800 units vs 5,000). Management highlighted product breadth enabling capture of procedural trends (open, laparoscopic, robotic).
Launch of OviTex LTR (Fully Resorbable Portfolio)
Full U.S. commercial launch of OviTex LTR on April 1, 2026 — positioned as one of the only fully resorbable tissue-based hernia solutions, priced comparably to preserve value proposition; early field feedback reported as overwhelmingly positive.
Commercial Organization Fully Staffed
U.S. commercial organization now fully staffed at expected 2026 levels with the largest field team in company history. Approximately 40% of the field team was hired between Q4 and Q1 and a material portion will reach the 6-month breakeven/inflection point by end of Q2, supporting expected productivity gains in H2.
Adjunct Product Momentum (LiquiFix)
LiquiFix noted as a meaningful addition with greater than 50% year-over-year growth, helping engage new surgeons and expand account penetration.
Growing Clinical Evidence and Thought-Leader Support
New meta-analysis presented at SAGES and additional published evidence reported that OviTex is safe and effective with significantly lower recurrence rates vs competitors; management emphasized influential authors and real-world data reinforcing the value proposition.
Board Refresh with Industry Experience
Board changes announced to add four new directors with deep med-tech and scaling experience, intended to provide strategic guidance for the company’s next phase of commercial execution and path to profitability.
Gross Profit Stability
Gross profit in Q1 2026 was $12.5M, essentially in line with the prior year period, demonstrating underlying cost structure resilience despite mix and inventory effects.
TELA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TELA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $1.02 | $0.96 | -5.88% |
Mar 24, 2026 | $0.76 | $0.69 | -9.33% |
Nov 13, 2025 | $1.11 | $1.00 | -9.91% |
Aug 11, 2025 | $1.86 | $1.60 | -13.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does TELA Bio (TELA) report earnings?
TELA Bio (TELA) is schdueled to report earning on Aug 12, 2026, Before Open (Confirmed).
What is TELA Bio (TELA) earnings time?
TELA Bio (TELA) earnings time is at Aug 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TELA EPS forecast?
TELA EPS forecast for the fiscal quarter 2026 (Q2) is -0.17.